Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study

Zegui Huang1,2†, Xiong Ding3†, Qing Yue4, Xianxuan Wang1,2, Zekai Chen5, Zefeng Cai2, Weijian Li1,2, Zhiwei Cai1,2, Guanzhi Chen6, Yulong Lan2, Weiqiang Wu2, Shouling Wu7* and Youren Chen2*

Abstract

Background: It has been suggested that the baseline triglyceride-glucose (TyG) index, a simple surrogate measure for insulin resistance, is significantly associated with the occurrence of stroke. Nevertheless, the impact of longitudinal patterns of TyG on the stroke risk in hypertensive patients is still unknown. Hence, this study aimed to investigate the association between TyG index trajectory and stroke risk among hypertensive patients.

Methods: This prospective study included 19,924 hypertensive patients from the Kailuan Study who underwent three waves survey and were free of myocardial infarction, cancer and stroke before or during 2010. The TyG index was calculated as ln [fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2], and latent mixed modelling was used to identify the trajectory of TyG during the exposure period (2006–2010). Furthermore, the Cox proportional hazard models were applied to estimate the hazard ratio (HR) and 95% confidence interval (CI) for incident stroke of different trajectory groups.

Results: Five distinct TyG trajectory were identified during 2006–2010: low-stable (n = 2483; range, 8.03–8.06), moderate low-stable (n = 9666; range, 8.58–8.57), moderate high-stable (n = 5759; range, 9.16–9.09), elevated-stable (n = 1741; range, 9.79–9.75), and elevated-increasing (n = 275; range, 10.38–10.81). During the median follow-up of 9.97 years, 1,519 cases of incident stroke were identified, including 1,351 with ischemic stroke and 215 with hemorrhage stroke. After adjusting for confounding variables, the HR and 95% CI of stroke were 2.21 (1.49, 3.28) for the elevated-increasing group, 1.43 (1.13, 1.83) for the elevated-stable group, 1.35 (1.10, 1.64) for the moderate high-stable group, 1.26 (1.06, 1.52) for the moderate low-stable group, respectively, when compare with the low-stable group. Similar results were observed in ischemic stroke, but a significant association was not found between TyG trajectory and risk of hemorrhage stroke.

Conclusion: A long-term elevated TyG index in hypertensive patients is associated with an increased risk of stroke, especially ischemic stroke. This finding implies that regular monitoring of TyG index may assist in identifying individuals at a higher risk of stroke among patients with hypertension.

†Zegui Huang and Xiong Ding contributed equally to this work
*Correspondence: drwusl@163.com; yrchen3@stu.edu.cn
1 Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, 69 Dongxia North Road, Shantou 515000, China
2 Department of Cardiology, Kailuan General Hospital, 57 Xinhua East Road, Tangshan 063000, China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Triglyceride-glucose index, Trajectory, Insulin resistance, Stroke, Hypertension

Background
Stroke is still the primary cause for disability and mortality in view of the 2019 Global Burden of Disease Study [1]. Stroke has more than two million new cases per year and is related to the largest life-year disability-adjusted loss for any disease in China, indicating an increasing and high burden of stroke [2]. Existing evidence has shown that hypertension is a major risk factor for stroke, occupying 2/3 of stroke in developing countries and 1/3 in developed countries [3, 4]. The absolute burden and prevalence of hypertension are increasing worldwide, particularly in low- and middle-income countries [5]. A national survey published in 2018 revealed that the weighted prevalence of hypertension in Chinese adults was 23.2%, equivalent to approximately 244 million patients [6]. Compared to a relatively healthy population, hypertensive patients have a greater likelihood of suffering from a stroke. Therefore, it is essential to identify the population at a high risk of stroke in hypertensive patients and better prevent the occurrence of stroke.

Abnormal glucose and lipid metabolism are very commonplace in individuals with hypertension, while insulin resistance (IR) plays a vital role in this biological process [7–9]. IR has been proven to be largely responsible for endothelial dysfunction and is regarded as a key risk factor for the occurrence and development of stroke [10, 11]. The hyperinsulinemic-euglycemic clamp test is the golden-standard way of assessing IR, whose result is accurate but time-consuming and labor-intensive [12]. Recently, the TyG index has been shown to be a simple and reliable surrogate index for IR, as calculated by fasting triglyceride (TG) and fasting plasma glucose (FPG) (eves [13, 14]. It is well established that elevated TyG increases the stroke risk in general population [15, 16], but the report about hypertensive patients is limited. In addition, the TyG index is susceptible to changes caused by many external factors. However, previous studies on the association between stroke risk and TyG index only used a single measure of TyG level and did not explore the longitudinal association between changes in TyG over time and stroke events in patients with hypertension.

Therefore, in the present study, we aim to determine the relationship between the longitudinal patterns of TyG index and stroke risk in hypertensive patients by using TyG trajectory during a 4-year period from the Kailuan study cohort (Registration Number: CHICTR-TNRC-11001489).

Methods
Study design and participants
The Kailuan Study is a large community-based, prospective cohort study to assess the risk factors and progression of CVD, conducted in Tangshan City, China. The detailed study design and methodology have been introduced previously [17, 18]. From 2006 to 2007, employees and retirees of the Kailuan Group at the age of 18–98 were recruited to participate in the baseline survey. Then, they underwent a comprehensive biennial health examination and a questionnaire on medication history, lifestyle factors, and demographic characteristics. A total of 57,914 participants who all participated in the first three surveys (2006–2007, 2008–2009 and 2010–2011) were enrolled in this study. Among them, 23,057 patients with hypertension were identified in the baseline survey (2006–2007). In the current study, 388 patients with myocardial infarction and 577 patients with stroke before 2006, 478 patients with myocardial infarction and 1,046 patients with stroke during 2006–2011 were excluded. Moreover, participants with missing TG or FPG data (n = 416), and cancer (n = 228) in or before the third wave survey (2010–2011) were excluded as well. Finally, 19,924 hypertensive participants were included in this study analysis (Additional file 1: Fig. S1). Also, the TyG index trajectory was established over the exposure period (from 2006 to 2010) to predict stroke risk in participants with hypertension from 2010 to 2020. This study was approved by the Ethics Committee of the Kailuan General Hospital and carried out based on the Declaration of Helsinki, with written informed consent provided by all participants.

Data collection and definition
All participants underwent baseline and follow-up surveys in 11 hospitals in the Kailuan community. A self-report questionnaire by trained staff was used to collect information on demographic characteristics, disease history (hypertension, diabetes, CVD, etc.), medication history (lipid-lowering, hypoglycemic, and antihypertensive drugs, etc.), and lifestyle factors (physical activity, drinking status, and smoking status etc.). A tape rule was used for measuring the height to the nearest 0.1 cm, and a calibrated platform scale was used for measuring weight to the nearest 0.1 kg when participants were shoeless and wore light clothes. Body mass index (BMI) was measured by dividing body weight (kg) by the square of height (m²). In addition, blood pressure (BP) was detected at least twice in the right upper arm with a calibrated mercury
sphygmomanometer when participants were in a seated posture. If the difference between the two measured values was ≥5 mmHg, BP was measured again, and the average results of the three measured values of BP were recorded.

Current-smoker was defined as smoking for over 1 year, smoking on average ≥1 cigarette/d, and still smoking in the last year. Current-drinker was defined as drinking for over 1 year, drinking on average ≥100 ml/d, and still drinking in the last year. Educational level was divided into junior high school or below, and senior high school or above. Active physical exercise was defined as exercise ≥4 times a week, each time duration at least 20 min. Atrial fibrillation was diagnosed according to the following electrocardiograph criteria: (1) irregular R-R intervals; (2) absence of repeating P waves; and (3) irregular atrial activity, in line with the European Society of Cardiology guidelines [19]. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, or/and diastolic blood pressure (DBP) ≥90 mmHg, or/and taking antihypertensive drugs in the past two weeks [20]. Diabetes mellitus was defined as FPG ≥7.0 mmol/L, or/and having a history of clearly diagnosed diabetes or/and taking hypoglycemic drugs [21].

Biochemical indicators and TyG index
Blood samples were collected from the antecubital vein of participants in the morning after overnight fasting for at least 8 h. Biochemical indicators such as high-sensitivity C-reactive protein (hs-CRP), FPG, TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC) were tested by examiners using an automatic analyzer (Hitachi 747, Tokyo, Japan) at the central laboratory of hospital. The TyG index was measured ln (fasting TG [mg/dL] × FPG [mg/dL]/2), as previously described [22].

Assessment of stroke
The primary outcome of this study was the first occurrence of stroke. The subgroup of stroke includes hemorrhagic stroke and ischemic stroke, while hemorrhagic stroke also includes intracerebral hemorrhage and subarachnoid hemorrhage. Assessments of stroke incidence were conducted once a year during the follow-up period, as described previously [23]. To be brief, potential stroke events was ascertained from 4 complementary sources: (1) Municipal Social Insurance Institution, which covered all participants, (2) Hospital Discharge Register centers, (3) death certificates, and (4) questionnaire survey (biennially since 2006). Potential cases of stroke included those who were identified by the ICD-10 (I60 to I61 for hemorrhagic stroke, and I63 for ischemic stroke) [24] based on the first 3 sources or those who self-reported in questionnaire survey. Stroke was diagnosed by brain computed tomography or magnetic resonance imaging scans, combined with neurological symptoms and signs according to the World Health Organization criteria [25]. Additionally, annual discharge records were collected and reviewed by a group of experienced experts to confirm suspected stroke cases. Fatal stroke cases were determined by medical records, autopsy reports, or death certificates with stroke as the underlying cause of death. The cases of nonfatal stroke were classified as the sudden onset of focal neurological deficit with vascular mechanism lasting more than 24 h. All participants were followed up until incident stroke diagnosis, death or December 31, 2020, whichever came first.

Statistical analysis
All statistical analyses were conducted using the SAS 9.4 (SAS Institute, Inc, Cary, NC) software. The TyG trajectory during 2006 to 2010 in hypertensive patients was identified by latent mixed modelling within the Proc Traj procedure of SAS [26–28]. The Bayesian information criterion (BIC) was adopted to assess the model fit and determine the model with five patterns as the best fit.

For the baseline description, continuous variables with a skewed distribution were considered to be the median with an interquartile range (25–75%), and continuous, normally distributed variables were regarded as the mean ± standard deviation (SD). Number and percentage (%) were used to describe categorical variables. According to distribution, the Kruskal Wallis test or one-way analysis of variance was used for comparisons of continuous variables and the chi-square test was conducted to analyze categorical variables. The incidence density was measured as the number of events divided by the total person-years of follow-up and presented as events per 1000 person-years. Kaplan–Meier method was used to compute stroke and its subgroup cumulative incidence of each trajectory group and the log-rank test was used for comparison. Additionally, the Cox proportional hazard models were established to analyze the HR and 95% CI of stroke for other trajectory groups when compare with the low-stable group and the proportional hazards assumption was satisfied. Model 1 adjusted for sex and age. Model 2 adjusted for sex, age, heart rate, BMI, SBP, DBP, hs-CRP, TC, current-smoker (yes or no), current-drinker (yes or no), active physical activity (yes or no), education level (junior high school or below, and senior high school or above), atrial fibrillation (yes or no) and diabetes mellitus (yes or no). Further adjustments were made for the use of antihypertensive drugs (yes or no), hypoglycemic drugs (yes or no), and lipid-lowering drugs (yes or no) in the model 3. Moreover, subgroup analyses were stratified by sex, age (<60 years vs. ≥60 years),
BMI (<28 kg/m² vs ≥ 28 kg/m²) and BP (<140/90 mmHg vs ≥ 140/90 mmHg).

Several sensitivity analyses were performed to verify the robustness of the results. First, to examine whether this association could be explained by a single TyG during the follow-up, additional adjustments were made for TyG in 2006 and TyG in 2010, respectively. Second, considering the change of covariates during 2006–2010, we additionally conducted a sensitivity analysis of adjusting for the change degree of covariates. Third, outcome events occurring in the first year of follow-up were excluded to minimize potential reverse causality. Fourth, participants with the history of atrial fibrillation were excluded given the impact of atrial fibrillation on the stroke risk. Finally, taking account of the effects of different drug treatments on the results, we also conducted three sensitivity analyses of excluding participants using antihypertensive drugs, hypoglycemic drugs or lipid-lowering drugs, respectively. In this study, statistical significance was indicated as $p < 0.05$ (two-sided test).

**Results**

**Baseline characteristics**

The baseline characteristics of participants were shown in Table 1. A total of 19,924 hypertensive participants were included in this study, whose mean age at the baseline was 56.78 ± 11.13 years. Of them, 16,342 (82.02%) were men and 3,582 (17.98%) were women. In the present study, five distinct trajectory patterns were identified by latent mixed modelling according to the TyG index change patterns from 2006 to 2010 (Fig. 1): the participants (n = 2483) who maintained low TyG levels (mean TyG range, 8.03–8.06, referred to as the “low-stable” group), the participants (n = 9666) who consistently had moderate-low TyG level (mean TyG range, 8.58–8.57, referred to as the “moderate low-stable” group), the participants (n = 5759) who maintained moderate-high TyG level (mean TyG range, 9.16–9.09, referred to as the “moderate high-stable” group), and the participants (n = 1741) who consistently had elevated TyG level (mean TyG range, 9.79–9.75, referred to as the “elevated-stable” group), and the participants (n = 275) who began with elevated and then had a slight increasing TyG level (mean TyG range, 10.38–10.81, referred to as the “elevated-increasing” group). Relative to the low-stable group, participants in the elevated-stable and elevated-increasing group were more likely to be young person, current smokers, current drinkers and had higher heart rate, BMI, SBP, DBP, total cholesterol, and hs-CRP levels, while featured with the higher prevalence of diabetes mellitus and proportion of drugs treatment.

**Relationship between stroke risk and TyG index trajectory**

After a median follow-up of 9.97 years, 1,519 cases of incident stroke were identified (1,351 with ischemic stroke, and 215 with hemorrhagic stroke). The Kaplan–Meier curve showed that participants in the elevated-increasing TyG group had a higher risk of stroke, ischemic stroke instead of hemorrhagic stroke than those in other trajectory groups (log-rank test, $p < 0.0001$, Fig. 2a, b; $p = 0.6132$, Fig. 2c). After adjusting for potential confounders, the HR and 95% CI for stroke, ischemic stroke and hemorrhagic stroke were 2.21 (1.49, 3.28), 2.16 (1.42, 3.29) and 1.77 (0.58, 5.37) in the elevated-increasing group, 1.43 (1.13, 1.83), 1.51 (1.16, 1.95) and 1.02 (0.55, 1.90) in the elevated-stable...
Fig. 2 Kaplan–Meier curves of incidence of outcomes according to TyG index trajectory. a Stroke; b Ischemic stroke; c Hemorrhage stroke
group, 1.35 (1.10,1.64), 1.40 (1.13,1.73) and 0.86 (0.54,1.38) in the moderate high-stable group, 1.26 (1.06,1.52), 1.30 (1.07,1.57) and 0.94 (0.63,1.40) in the moderate low-stable group, respectively, when compared with the low-stable group (Table 2).

**Table 2** Baseline characteristics of 19924 hypertensive patients according to the trajectories of TyG index from 2006 to 2010

| Variables                        | Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing | P  |
|----------------------------------|------------|---------------------|----------------------|----------------|---------------------|----|
| N                                | 2483       | 9666                | 5759                 | 1741           | 275                 |    |
| Age, years                       | 59.38±11.35| 57.29±11.35         | 55.76±10.71          | 54.49±10.13    | 51.88±9.29          | <0.01|
| Male n (%)                       | 2029 (81.72)| 7886 (81.58)        | 4708 (81.75)         | 1478 (84.89)   | 241 (87.64)         | <0.01|
| Heart rate, beats/min            | 72.72±10.62| 73.97±10.91         | 75.51±11.29          | 77.89±11.77    | 78.69±10.54         | <0.01|
| BMI, kg/m²                       | 24.31±3.27 | 25.61±3.33          | 26.68±3.31           | 26.99±3.29     | 27.01±3.30          | <0.01|
| SBP, mmHg                        | 148.03±19.51| 140.69±19.11       | 142.21±18.73         | 143.69±19.16   | 142.43±17.13        | <0.01|
| DBP, mmHg                        | 87.89±10.71| 88.89±10.71         | 90.09±10.68          | 90.93±11.11    | 91.65±10.38         | <0.01|
| Total cholesterol, mmol/L        | 4.67±0.87  | 4.95±0.92           | 5.23±1.03            | 5.43±1.17      | 6.44±1.79           | <0.01|
| hs-CRP, mmol/L                  | 1.26 (0.62, 3.01)| 1.04 (0.40, 2.60)   | 1.30 (0.50, 3.10)    | 1.60 (0.70, 3.70)| 1.61 (0.90, 3.72)   | <0.01|
| TyG in 2006                     | 7.94±0.34  | 8.55±0.37           | 9.22±0.44            | 9.84±0.52      | 10.45±0.60          | <0.01|
| TyG in 2008                     | 7.91±0.32  | 8.56±0.36           | 9.15±0.42            | 9.87±0.53      | 10.67±0.63          | <0.01|
| TyG in 2010                     | 7.97±0.32  | 8.53±0.38           | 9.13±0.44            | 9.81±0.49      | 10.86±0.61          | <0.01|
| Current smoker, n (%)            | 800 (32.22)| 3416 (35.34)        | 2251 (39.09)         | 794 (45.61)    | 136 (49.45)         | <0.01|
| Current drinker, n (%)           | 698 (28.11)| 2983 (30.86)        | 2126 (36.92)         | 761 (43.71)    | 134 (48.73)         | <0.01|
| Active physical activity, n (%)  | 415 (16.71)| 1573 (16.27)        | 865 (15.02)          | 230 (13.21)    | 42 (15.27)          | <0.01|
| Senior high school or above, n (%)| 351 (14.14)| 1865 (19.29)        | 1240 (21.53)         | 376 (21.60)    | 64 (23.27)          | <0.01|
| Atrial fibrillation, n (%)       | 33 (1.33)  | 90 (0.93)           | 43 (0.75)            | 10 (0.57)      | 0 (0.00)            | 0.02 |
| Diabetes mellitus, n (%)         | 47 (1.89)  | 648 (6.70)          | 1296 (22.50)         | 793 (45.55)    | 176 (64.01)         | <0.01|
| Lipid-lowering drugs, n (%)      | 9 (0.36)   | 82 (0.85)           | 114 (1.98)           | 53 (3.04)      | 13 (4.73)           | <0.01|

TyG triglyceride-glucose index, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, hs-CRP high-sensitivity C-reactive protein

Subgroup and sensitivity analysis

The results of the subgroup analysis were shown in Table 3, and we did not find significant interaction between the TyG trajectories and age, sex, BMI or BP. In the sensitivity analyses, there was no substantial change in the relationship between TyG index trajectory and stroke risk after additional adjustment for the TyG index in 2006 or 2010 (Additional file 2: Table S1, S2). In addition, the results of adjusting for the change degree of covariates, excluding outcome events that occurred in the first year of follow-up (n=97) or excluding participants with history of atrial fibrillation (n=176) was still consistent with the main results (Additional file 2: Table S3–S5). Furthermore, after excluding participants who receiving treatment with the use of lipid-lowering (n=271), hypoglycemic (n=1081) or anti-hypertensive drugs (n=4512), respectively, the result still was steady (Additional file 2: Table S6).

Discussion

Five different TyG trajectory patterns for 4 years were identified in this prospective study of 19,924 participants with hypertension from the Kailuan study. Hypertensive patients with a long-term high TyG level, as compared with those in the low-stable group, had a higher risk of stroke and ischemic stroke during the follow-up of 10 years, independent of the baseline TyG. Nevertheless, no significant association was observed between TyG index trajectory and hemorrhagic stroke. Similar results were also found in the subgroup and sensitivity analyses.

The relationship between TyG index and incidence of stroke has been widely investigated in the general population. A cross-sectional study from the rural areas of northeast China indicated that the elevated TyG level is an independent risk factor for stroke and ischemic stroke after a median follow-up of 10 years, independent of the baseline TyG. Nevertheless, no significant association was observed between TyG index trajectory and hemorrhagic stroke. Similar results were also found in the subgroup and sensitivity analyses.
the studies were conducted in relatively healthy population and very few studies have explored the relationship between TyG index and stroke incidence in hypertensive patients at a high risk of stroke. To our knowledge, only in a cohort study among elderly patients with hypertension, Hu et al. found a positive association between TyG index and the risk of first stroke [31]. Furthermore, previous studies in the general population or hypertensive patients only focused on a single TyG measurement without considering the long-term effect of TyG changes over time on stroke. In this study, trajectories were used to present the TyG change patterns over 4 years to observe its long-term effect on the risk of stroke among hypertensive patients. Our baseline results are consistent with previous findings in patients with hypertension [31, 32], showing that the highest TyG was in the youngest patients with hypertension. Moreover, our previous work has shown that TG level in the young people is generally higher than in the older, which was also found in the other studies [33–35]. After adjusting for potential confounding factors, our study extended the current database by indicating that hypertensive patients with a long-term elevated TyG level had a higher risk of stroke and ischemic stroke, relative to those with a low-stable TyG index. Moreover, the association was not attenuated through additionally adjusting for baseline TyG level. Therefore, routine monitoring of the TyG index may be helpful for identifying people at higher risk of stroke in hypertensive patients, providing new evidence for the prevention of stroke in clinical practice.

However, no association was observed between the TyG index trajectory and hemorrhagic stroke, a subtype of stroke with relatively low incidence. In this study, patients with hypertension in the elevated-increasing group have no significant increased risk of hemorrhagic stroke. Wang et al. showed that the baseline and long-term cumulative mean TyG index could predict the risk of stroke and ischemic stroke instead of intracerebral hemorrhage in the general population [16]. Additionally, a meta-analysis of 11 studies also revealed that the TyG index had no association with hemorrhagic stroke, indirectly supporting our results in hypertensive patients [36]. It is noteworthy that hypertension is an independent risk factor for hemorrhagic stroke [37], but a meta-analysis reported that hyperlipidemia may provide the effect of preventing vascular bleeding and the hemorrhagic stroke risk decreases by 7% per 1 mmol/L TG increase [38]. Therefore, the combined effect of the two opposite effects may cause non-significant statistical relevance in the TyG index trajectory and hemorrhagic stroke among hypertensive patients.

Table 2 The hazard ratio (HR) of stroke and its subgroup in hypertensive patients according to trajectories of TyG from 2006 to 2010

|                  | Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing |
|------------------|------------|---------------------|----------------------|-----------------|---------------------|
| **Stroke**       |            |                     |                      |                 |                     |
| Case/Total       | 149/2483   | 715/9666            | 460/5759             | 159/1741        | 36/275              |
| IR               | 6.52       | 7.97                | 8.62                 | 9.91            | 14.67               |
| Model 1          | 1 (reference) | 1.33 (1.11, 1.58)  | 1.53 (1.27, 1.85)    | 1.84 (1.47, 2.31)| 2.97 (2.06, 4.29)  |
| Model 2          | 1 (reference) | 1.27 (1.07, 1.53)  | 1.35 (1.11, 1.64)    | 1.44 (1.12, 1.84)| 2.24 (1.51, 3.32)  |
| Model 3          | 1 (reference) | 1.26 (1.06, 1.52)  | 1.35 (1.10, 1.64)    | 1.43 (1.13, 1.83)| 2.21 (1.49, 3.28)  |
| **Ischemic stroke** |           |                     |                      |                 |                     |
| Case/Total       | 127/2483   | 628/9666            | 417/5759             | 147/1741        | 32/275              |
| IR               | 5.54       | 6.98                | 7.79                 | 9.13            | 12.95               |
| Model 1          | 1 (reference) | 1.37 (1.13, 1.66)  | 1.64 (1.34, 2.01)    | 2.01 (1.58, 2.55)| 3.11 (2.10, 4.60)  |
| Model 2          | 1 (reference) | 1.31 (1.07, 1.58)  | 1.41 (1.14, 1.74)    | 1.52 (1.17, 1.97)| 2.20 (1.45, 3.34)  |
| Model 3          | 1 (reference) | 1.30 (1.07, 1.57)  | 1.40 (1.13, 1.73)    | 1.51 (1.16, 1.95)| 2.16 (1.42, 3.29)  |
| **Hemorrhagic stroke** |         |                     |                      |                 |                     |
| Case/Total       | 32/2483    | 106/9666            | 54/5759              | 19/1741         | 4/275               |
| IR               | 1.37       | 1.15                | 0.98                 | 1.14            | 1.52                |
| Model 1          | 1 (reference) | 0.89 (0.60, 1.32)  | 0.79 (0.51, 1.24)    | 0.96 (0.54, 1.70)| 1.37 (0.48, 3.89)  |
| Model 2          | 1 (reference) | 0.92 (0.62, 1.39)  | 0.84 (0.52, 1.36)    | 0.99 (0.53, 1.86)| 1.71 (0.56, 5.19)  |
| Model 3          | 1 (reference) | 0.94 (0.63, 1.40)  | 0.86 (0.54, 1.38)    | 1.02 (0.55, 1.90)| 1.77 (0.58, 5.37)  |

TyG triglyceride-glucose index, IR incidence rate (per 1000 person-years); Model: 1 adjusted for age, sex; Model 2: adjusted for heart rate, BMI, SBP, DBP, total cholesterol, hs-CRP, current smoker, current drinker, physical activity, education level, diabetes mellitus and atrial fibrillation on the basis of model 1; Model 3: included variables in model 2 and further adjusted for hypoglycemic drugs, anti-hypertensive drugs and lipid-lowering drugs.
inflammation, coagulation dysfunction, and oxidative stress, which may lead to the occurrence of hypertension, diabetes, and hyperlipidemia [39–41]. In our study, hypertensive patients in the elevated-increasing group also have a higher prevalence of diabetes mellitus and hyperlipidemia, increasing the risk of stroke jointly. Second, arterial stiffness is a key component of the pathogenesis of stroke [42], and IR plays a key role in endothelial dysfunction and enhances the atherosclerotic process [43]. Previous studies have indicated that the elevated TyG level has a significant association with arterial stiffness in the population with hypertension [32, 44]. At last, participants with a long-term high TyG level have higher BMI, heart rate, SBP, DBP, and TC levels, and tend to be current smokers or drinkers, which are the common risk factor for stroke. Thus, it may lead to a significantly increased risk of stroke.

The strengths of the present study include that it is the first large prospective study to investigate the association of longitudinal pattern of TyG index and stroke risk among patients with hypertension. The trajectories were used to represent changes in TyG level over time in hypertensive patients and the possible confounders affecting the risk of stroke were adjusted in the analysis, which ensures the reliability of the outcomes to some extent. However, several limitations should be noted in this study. First, the homoeostasis model assessment of IR (HOMA-IR) or the hyperinsulinemic-euglycemic clamp test of IR was not conducted on participants, but these methods of assessment are complex and expensive, thus, it is not suitable for routine monitoring. Furthermore, the TyG index have been proven to be great associate with insulin clamp test and HOMA-IR, as a simple surrogate index [45, 46]. Second, the causal relationship between the TyG index trajectory and stroke risk in

### Table 3: Subgroup analyses: the hazard ratio (HR) of stroke in hypertensive patients according to trajectories of TyG From 2006 to 2010

|                      | Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing | P for interaction |
|----------------------|------------|---------------------|----------------------|----------------|---------------------|------------------|
| **Sex**              |            |                     |                      |                |                     |                  |
| Male                 | 125/2029   | 632/7886            | 402/4708             | 134/1478       | 31/241              | 0.06             |
| 1 (reference)        | 1.37 (1.13, 1.67) | 1.46 (1.18, 1.81) | 1.47 (1.12, 1.92)   | 2.25 (1.46, 3.44) |                     |                  |
| Female               | 24/454     | 83/1780             | 58/1051              | 25/263         | 5/34                |                  |
| 1 (reference)        | 0.77 (0.48, 1.23) | 0.81 (0.48, 1.35) | 1.26 (0.67, 2.36)   | 2.28 (0.82, 6.33) |                     |                  |
| **Age**              |            |                     |                      |                |                     | 0.80             |
| Age < 60 y           | 57/1346    | 359/5897            | 267/3860             | 103/1278       | 27/232              |                  |
| 1 (reference)        | 1.38 (1.04, 1.83) | 1.40 (1.05, 1.91) | 1.42 (1.00, 1.98)   | 2.01 (1.23, 3.29) |                     |                  |
| Age ≥ 60 y           | 92/1137    | 356/3769            | 193/1899             | 56/463         | 9/43                |                  |
| 1 (reference)        | 1.21 (0.96, 1.53) | 1.34 (1.02, 1.76) | 1.65 (1.14, 2.38)   | 3.25 (1.58, 6.70) |                     |                  |
| **BMI**              |            |                     |                      |                |                     | 0.15             |
| BMI < 28             | 128/2187   | 554/7604            | 305/3949             | 118/1148       | 19/174              |                  |
| 1 (reference)        | 1.29 (1.06, 1.57) | 1.35 (1.08, 1.68) | 1.65 (1.26, 2.17)   | 2.02 (1.20, 3.33) |                     |                  |
| BMI ≥ 28             | 21/296     | 161/2062            | 155/1810             | 41/593         | 17/101              |                  |
| 1 (reference)        | 1.12 (0.70, 1.80) | 1.21 (0.75, 1.95) | 0.95 (0.54, 1.67)   | 2.47 (1.23, 4.97) |                     |                  |
| **BP**               |            |                     |                      |                |                     | 0.83             |
| BP < 140/90 mmHg     | 39/951     | 178/3484            | 109/1784             | 34/517         | 6/71                |                  |
| 1 (reference)        | 1.21 (0.85, 1.72) | 1.34 (0.90, 1.98) | 1.28 (0.77,2.13)    | 1.64 (0.65, 4.07) |                     |                  |
| BP ≥ 140/90 mmHg     | 110/1532   | 537/6182            | 351/3975             | 125/1224       | 30/204              |                  |
| 1 (reference)        | 1.27 (1.03, 1.57) | 1.32 (1.05, 1.65) | 1.47 (1.11, 1.94)   | 2.42 (1.56, 3.75) |                     |                  |

TyG triglyceride-glucose index; Adjusted for age, sex, heart rate, BMI, SBP, DBP, total cholesterol, hs-CRP, current smoker, current drinker, physical activity, education level, diabetes mellitus, atrial fibrillation, hypoglycemic drugs, anti-hypertensive drugs and lipid-lowering drugs.
hypertensive patients cannot be demonstrated because it was an observational study. Third, the diagnosis of diabetes was based on a single measurement of FPG but not oral glucose tolerance test (OGTT) and hemoglobin A1c (HbA1c) level might underestimate the diabetes incidence. Furthermore, the hypoglycemic drugs in this study specifically refer to oral hypoglycemic drugs, and we did not collect the information of insulin or glucose-lowering treatments plus dietary control, which may have a slight effect on the results. Finally, the participants in this study were restricted to northern Chinese adults who live in the Kailuan community, and fewer of them are women, thus, the generalizability is relatively limited. Further studies with multiple regions, ethnicities, populations, particularly those with a balanced proportion of men and women, are still warranted to validate our results.

Conclusions
In conclusion, a long-term elevated TyG index in hypertensive patients is associated with an increased risk of stroke and ischemic stroke, but no significant association was found between TyG index trajectory and risk of hemorrhagic stroke. These findings highlight the importance of monitoring longitudinal TyG index patterns and early controlling glucose and lipid to prevent the occurrence of stroke among patients with hypertension.

Abbreviations
TyG index: Triglyceride-glucose index; IR: Insulin resistance; CVD: Cardiovascular disease; TG: Triglyceride; FPG: Fasting plasma glucose; BMI: Body mass index; BP: Blood pressure; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TC: Total cholesterol; HDL-C: High-density lipoprotein-cholesterol; hsCRP: High-sensitivity C-reactive protein; LDL-C: Low-density lipoprotein-cholesterol; HR: Hazard ratio; CI: Confidence interval.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01577-7.

Additional file 1: Fig. S1. Flow chart of inclusion and exclusion. The flowchart of 19,924 hypertensive patients included in the final analyses.

Additional file 2: Table S1. Sensitivity Analysis of additionally adjusted for TyG in 2006. Table S2. Sensitivity Analysis of additionally adjusted for TyG in 2010. Table S3. Sensitivity Analysis of adjusted for the change degree of covariates from 2006 to 2010. Table S4. Sensitivity Analysis of excluding Outcome Events within the first year of follow-up. Table S5. Sensitivity Analysis of excluding participants with the history of atrial fibrillation. Table S6. Sensitivity Analysis of excluding participants with the use of anti-hypertensive drugs, hypoglycemic drugs or lipid-lowering drugs, respectively.

Acknowledgements
We sincerely express our gratitude to all parties in the Kailuan Study, as well as members of Kailuan General Hospital and its affiliated hospitals.

Author contributions
The study idea was designed by ZGH, SLW and YRC, ZGH, XD, QY, XXW, YLL, and ZKC analyzed and interpreted the data; ZGH, XD, ZFC, GZC, WJL, WQW, and ZWC were responsible for drafting the manuscript. The manuscript was reviewed by SLW and YRC. All authors read and approved the final manuscript.

Funding
This work has been supported by the National Natural Science Foundation of China (No. 81870312).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was performed according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Kailuan General Hospital (Approval Number: 2006–05) All participants were agreed to take part in the study and provided informed written consent.

Consent for publication
Not applicable.

Competing interests
None of the authors had any conflict of interest regarding any aspect of this manuscript.

Author details
1 Shantou University Medical College, Shantou, China. 2 Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, 69 Dongxia North Road, Shantou 515000, China. 3School of Public Health, Wuhuan University, Wuhuan, China. 4School of Public Health, North China University of Science and Technology, Tangshan, China. 5Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 6China Medical University, Shenyang, China. 7Department of Cardiology, Kailuan General Hospital, 57 Xinhua East Road, Tangshan 063000, China.

Received: 21 June 2022 Accepted: 19 July 2022
Published online: 27 July 2022

References
1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the gbd 2019 study [published correction appears in J Am Coll Cardiol 2021 Apr 20;77(15):1958-1959]. J Am Coll Cardiol. 2020;76(25):2982–3021.
2. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394–405.
3. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol. 2020;75(15):1804–18.
4. Cipolla MJ, Liebeskind DS, Chan SL. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab. 2018;38(12):2129–49.
5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
6. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344–56.
7. Sun X, Chen Y, Zeng Q, Huang X, Cai J. Reduction of leukocyte-derived H2(2)S linked to abnormal glycolipid metabolism in hypertensive subjects. Clin Exp Hypertens. 2017;39(5):427–34.
8. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr. 2014;12(1).28.
9. Yu S, Sun Z, Zheng L, Guo X, Yang H, Sun Y. Prevalence of diabetes and impaired fasting glucose in hypertensive adults in rural China: far from leveling-off. Int J Environ Res Public Health. 2015;12(1):14786–79.

10. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85.

11. Kernan WN, Inzucchi SE, Viscusi CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology. 2002;59:890–15.

12. Cerinósimo E, Solis-Herrera C, Trautmann M, Mally J, Triplitt C. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev. 2014;10(1):2–42.

13. Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18:361.

14. Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores JR, Simental-Mendia LE, Méndez-Cruz R, Murguía-Romero M, et al. Fasting triglycerides and glucose index as a diagnostic test for insulin resistance in young adults. Arch Med Res. 2016;47:382–7.

15. Shi W, Xing L, Jing L, et al. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: Insights from a general population. Nutr Metab Cardiovasc Dis. 2020;30(2):245–53.

16. Wang A, Wang G, Liu Q, et al. Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up. Cardiovasc Diabetol. 2021;20(1):46.

17. Wu S, An S, Li W, et al. Association of trajectory of cardiovascular health score and incident cardiovascular disease. JAMA Netw Open. 2019;2(15):e194758.

18. Zheng M, Zhang X, Chen S, et al. Arterial stiffness preceding diabetes: a longitudinal study. Circ Res. 2020;127(12):1491–8.

19. Camm AJ, Kirchhof P, Lip GL, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.

20. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

21. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7.

22. Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S, Wang A. Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20(1):19.

23. Li Y, Huang Z, Jin C, et al. Longitudinal Change of Perceived Salt Intake and Stroke Risk in a Chinese Population. Stroke. 2018;49(6):1332–9.

24. Wu S, Zhou D, Liu Y, et al. Association of TyG index and TG/HDL-C ratio with arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study. Cardiovasc Diabetol. 2020;19(1):139.

25. Stroke–1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders. Stroke 1989; 20:1407–31.

26. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2007;35:542–71.

27. Sharashova E, Wisgaard T, Ball J, et al. Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study. Eur Heart J. 2020;41(16):1554–62.

28. Zhao Y, Sun H, Zhang W, et al. Elevated triglyceride-glucose index predicts risk of incident ischaemic stroke: the Rural Chinese cohort study. Diabetes Metab. 2021;47(4):101246.

29. Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(1):361.

30. Hu L, Bao H, Huang X, et al. Relationship between the triglyceride glucose index and the risk of first stroke in elderly hypertensive patients. Int J Gen Med. 2022;15:1271–9.

31. Li M, Zhan A, Huang X, et al. Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study. Cardiovasc Diabetol. 2020;19(1):139.

32. Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores JR, Simental-Mendia LE, Méndez-Cruz R, Murguía-Romero M, et al. Fasting triglycerides and glucose index as a diagnostic test for insulin resistance in young adults. Arch Med Res. 2016;47:382–7.

33. Huang Z, Wang X, Ding X, et al. Association of age of metabolic syndrome onset with cardiovascular diseases: the kailuan study. Front Endocrinol (Lausanne). 2022;13:857985.

34. Wang C, Yuan Y, Zheng M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921–30.

35. Sattar N, Rawshani A, Franchin S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228–37.

36. Feng X, Yao Y, Wu L, Cheng C, Tang Q, Xu S. Triglyceride-glucose index and the risk of stroke: a systematic review and dose-response meta-analysis. Horm Metab Res. 2022;54(3):175–86.

37. Hägg-Holmberg S, Dahlstrom EH, Forsblom CM, et al. The role of blood pressure in risk of ischemic and hemorrhagic stroke in type 1 diabetes. Cardiovasc Diabetol. 2019;18(1):88.

38. Jin X, Chen H, Shi H, et al. Lipid levels and the risk of hemorrhagic stroke: a dose-response meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(1):23–35.

39. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care. 2003;26(5):1619–23.

40. Wang Y, Yang W, Jiang X. Association between triglyceride-glucose index and hypertension: a meta-analysis. Front Cardiovasc Med. 2021;8:4035.

41. Cortesi PA, Fornari C, Madotto F, et al. Trends in cardiovascular diseases burden and vascular risk factors in Italy: the Global Burden of Disease study 1990–2017. Eur J Prev Cardiol. 2021;28(4):385–96.

42. Chen Y, Shen F, Liu J, Yang GY. Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for stroke. Stroke Vasc Neurol. 2017;2(2):65–72.

43. Tallapragada DS, Karpe PA, Tkoo K. Long-lasting partnership between insulin resistance and endothelial dysfunction: role of metabolic memory. Br J Pharmacol. 2015;172(16):4012–23.

44. Wu Z, Zhou D, Liu Y, et al. Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population. Cardiovasc Diabetol. 2021;20(1):134.

45. Guerrero-Romero F, Simental-Mendia LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51.

46. Vasques AC, Novaes FS, de Oliveira MS, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2021;194(7):10251.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.